Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Creative Biogene provides tumorigenicity testing services for stem cells or cell lines with potential tumorigenic risk. The service evaluates the potential of a cell substrate to form tumors in vivo, ensuring that cell substrates used in biologics manufacturing do not carry unacceptable tumorigenic risk. According to the ICH S6(R1) risk‑based assessment framework, tumorigenicity testing should be guided by cell substrate characteristics and clinical application, rather than being a default requirement.
Tumorigenicity refers to the ability of a cell substrate to form tumors in animals. The assessment focuses on whether cells possess uncontrolled proliferative potential and carry transforming factors that induce tumor formation. Note the distinction from tumor-forming ability (tumorigenicity in the narrow sense): the latter concerns whether the cell substrate itself can form tumors, whereas tumorigenicity (broader) focuses on the presence of immortalizing and tumorigenic factors within the cells. Creative Biogene covers two core testing methods: the in vivo nude mouse assay (gold standard) and the in vitro soft agar colony formation assay (important complementary method).
| Guideline / Document | Relevant Section | Core Requirements |
| ICH S6(R1) | Preclinical Safety Evaluation of Biotechnology‑Derived Pharmaceuticals | Provides a flexible framework; tumorigenicity assessment should be risk‑based, considering cell substrate characteristics and clinical use, not a default requirement. |
| WHO TRS 978, Annex 3 | Recommendations for the Evaluation of Cell Substrates | General recommendations for cell substrate evaluation, including tumorigenicity testing. |
| FDA Guidance (1993 PTC) | Points to Consider in the Characterization of Cell Lines | Classic guidance for cell line characterization; remains an important reference for tumorigenicity testing. |
| EMA Guideline on Human Cell‑Based Medicinal Products | Tumorigenicity Assessment | States that tumorigenicity studies should be conducted when cell transformation risk is foreseeable, focusing on proliferation capacity and chromosomal integrity. |
| FDA Guidance on hESC‑Derived Products | Tumorigenicity Risk Evaluation | Considers control of undifferentiated stem cell or other cell impurity levels as a primary aspect of tumorigenicity risk evaluation. |
| Aspect | Tumorigenicity Testing | Tumor Forming Ability Testing |
| Target | Presence of immortalizing/tumorigenic factors in the cell substrate | Whether the cell substrate itself can form tumors in vivo |
| Object of detection | Cytokines, viral sequences, transforming factors | The cell substrate itself |
| Focus | Root cause assessment of transformation risk | Direct verification of the transformation outcome |
| Applicable scenarios | Genetically modified cells, cells carrying exogenous sequences | Newly established cell lines, vaccine production cell lines |
| Regulatory basis | ICH S6(R1) risk‑based | Chinese Pharmacopoeia, WHO |
These two concepts are often listed together in cell testing, but their targets and regulatory logic differ. The testing strategy should be selected based on cell substrate characteristics.
Test cells are inoculated subcutaneously or intramuscularly into immunodeficient animals (typically athymic nude mice). The lack of T cell immune response allows potentially tumorigenic cells to form tumors in vivo. Through long‑term observation (at least 16 weeks) and endpoint histopathological examination, the formation of progressive nodules or metastatic tumors is assessed.
This assay uses low-melting-point agarose to mimic the three‑dimensional microenvironment. Normal cells cannot grow in suspension, whereas transformed cells can form colonies in semi‑solid medium. It is a classic in vitro method for assessing anchorage‑independent growth.
The in vivo method is the gold standard, but for certain cells, in vitro results can serve as an important reference for tumorigenicity assessment, especially for low‑passage continuous cell lines that are non‑tumorigenic in animals.
This assay evaluates the malignant transformation potential of cells by detecting morphological changes, growth characteristics, and genetic instability under specific culture conditions. Phenotypic changes of transformed fibroblasts include tumorigenicity in hosts, colony formation in semi‑solid medium, and crisscrossed or piled‑up growth.
It serves as a complement to the soft agar colony formation assay for in‑depth assessment of transformation potential, particularly for genetically modified cells and stem cell‑derived products.
| Aspect | Nude Mouse In Vivo | Soft Agar Colony Formation | In Vitro Cell Transformation |
| Principle | Tumor formation in immunodeficient animals | Anchorage‑independent colony formation | Morphological + growth changes |
| Timeline | >16 weeks | ~3 weeks | 2‑4 weeks |
| Sensitivity | High (detects low levels) | Moderate | Moderate |
| Regulatory status | Gold standard (FDA/WHO/ChP) | Important complementary reference | Auxiliary assessment |
| Animal use | Required (≥30 mice/assay) | Not required | Not required |
| Applicability | All cell types | Continuous cell lines (complement to in vivo) | Genetically modified cells, stem cells |
| Readout | Tumor formation rate + histopathology | Colony formation rate + size | Transformation focus rate |
For detailed technical discussion on tumorigenicity testing necessity assessment, strategy design, or IND/BLA submission support for your cell line, please contact Creative Biogene’s technical team for a customized solution.
Q1: Is tumorigenicity testing required for all cell banks?
A: No. Under the ICH S6(R1) risk‑based framework, testing should be guided by cell substrate characteristics and clinical application, not a default. Continuous cell lines already proven to be tumorigenic (e.g., BHK21, CHO, C127) used for manufacturing therapeutic products may be exempt. Cell types that are intrinsically tumorigenic (e.g., hybridoma cells) may also be exempt. Non‑genetically modified diploid cells, after being proven non‑tumorigenic, may not require routine testing. However, for newly established cell lines, stem cells (ESC/iPSC), and genetically modified cells, tumorigenicity testing is generally necessary.
Q2: Why are CHO cells exempt from tumorigenicity testing?
A: CHO cells are known to be tumorigenic (they form tumors in nude mice). However, due to their long history of safe use, regulatory authorities accept them as production cell substrates. According to industry practice, continuous cell lines already proven tumorigenic (e.g., BHK21, CHO, C127) or intrinsically tumorigenic cell types (e.g., hybridoma cells) used for manufacturing therapeutic products may be exempt from further tumorigenicity testing. This does not mean CHO cells are “non‑tumorigenic”; rather, based on historical use and risk assessment, their tumorigenic characteristic is accepted as part of the cell substrate, and product safety is ensured through other controls (e.g., viral clearance validation of purification processes, final product impurity control).
Q3: What should be done if the positive control (HeLa cells) does not form tumors?
A: Positive control (HeLa or HeLa S3 cells) must form tumors to validate the test system. If the positive control group fails to form tumors within the observation period, the test is invalid. The cause must be investigated and the test repeated. Common causes include: low cell viability (HeLa viability <90%), insufficient cell number inoculated (<1×10⁷ cells/animal), animal strain issues (incomplete immunodeficiency), or insufficient observation period. Creative Biogene ensures that positive control tumor formation rates meet test validity criteria (≥80%).
Copyright © 2026 Creative Biogene. All rights reserved.